Tag Archives: Advisory Committee on Immunization Practices

Measles/Mumps/Rubella (MMR) vaccination and ‘informed consent’ – a letter to the NHMRC Australian Health Ethics Committee

Further to  my letter to the US Advisory Committee on Immunization Practices, challenging government mandated revaccination of children with the second dose of live Measles/Mumps/Rubella (MMR) vaccine.

I have now forwarded a letter on this matter to the NHMRC Australian Health Ethics Committee, challenging the Australian Government’s requirement for revaccination of children with a second dose of live MMR vaccine, as children are likely to be immune after the first dose of effective live MMR vaccine, given at the appropriate age (i.e. after maternally derived antibodies have waned).

Informed Consent 3The medical establishment, pharmaceutical industry, and governments are imposing an ever-increasing amount of lucrative vaccine products on healthy people.  Vaccines are medical interventions and it is imperative that citizens give their ‘informed consent’ to these interventions.  Children, i.e. ‘pre-citizens’, also have a right to bodily integrity, and it is essential that parents are properly informed before medical interventions for their children.

See below my detailed letter forwarded to Professor Ian Olver, Chair of the NHMRC Australian Health Ethics Committee.  The letter has also been forwarded to each member of the committee, see membership list also noted below.

______________________________________________

19 March 2014

Professor Olver

RE:    The Australian Government’s requirement for revaccination of children with a second dose of live Measles/Mumps/Rubella (MMR) vaccine / lack of ‘informed consent’ / adverse events 

The Australian Government’s National Immunisation Program Schedule stipulates that children receive two doses of live measles/mumps/rubella (MMR) vaccines[1], and meeting this requirement is linked to obtaining Immunisation Related Payments for Parents.[2]

However, according to the GlaxoSmithKline PRIORIX Product Information leaflet, most seronegative children are likely to be immune after one dose of live MMR vaccine.[3]

I question whether parents are being given the opportunity to properly give their ‘informed consent’ to the second dose of the live MMR vaccine (or the MMR+varicella i.e. GlaxoSmithKline PRIORIX-TETRA MMRV vaccine) for their children.  This question is particularly pertinent as adverse events have been reported after MMR and MMRV vaccination.

I request that the NHMRC Australian Health Ethics Committee respond to me on this matter, and I provide further supporting information below.

According to the PRIORIX Product Information Leaflet, in “a more recent study comparing the formulation of PRIORIX (albumin-free) with the previous formulation containing albumin, antibodies against measles, mumps and rubella were detected in 98.4, 94.8 and 100% of previously seronegative subjects (n=191)”.  The leaflet also contains similarly high seroconversion rates from earlier studies.[4]

The PRIORIX Product Information Leaflet notes that: “Seroconversion has been shown to equate with protection against each of the measles, mumps and rubella viruses.”[5] The National Immunisation Program Schedule recommends the first MMR vaccination at 12 months of age[6], so presumably it is expected that most children will be seronegative at this age, i.e. maternally derived antibodies will have waned.

Despite the fact it appears one dose of PRIORIX MMR live vaccine is likely to provide protection for previously seronegative subjects, the PRIORIX Product Information Leaflet indicates two doses are to be given, i.e. “The Australian NH&MRC Immunisation Handbook recommendations for MMR vaccination are as follows: MMR vaccine is recommended for all children at 12 months of age and again at 4-6 years of age unless there is a genuine contraindication.”[7]

It is notable that neither the PRIORIX[8] nor the PRIORIX-TETRA[9] Consumer Medicine Information leaflets contain information on the reportedly high seroconversion rates after live MMR vaccination.  Does this indicate that parents are not being informed of the reportedly high seroconversion rates after vaccination of previously seronegative children with the PRIORIX MMR vaccine product? 

It is also notable that there is no reference to the option of antibody titre testing to verify a response to MMR vaccination in either the Consumer Medicines Information leaflet or the Product Information leaflet for PRIORIX or PRIORIX-TETRA.

What are the ramifications here for ‘informed consent’?

The Australian Immunisation Handbook provides criteria for consent to vaccination to be legally valid, i.e.:

1.     It must be given by a person with legal capacity, and of sufficient intellectual capacity to understand the implications of being vaccinated.

2.     It must be given voluntarily in the absence of undue pressure, coercion or manipulation.

3.     It must cover the specific procedure that is to be performed.

4.     It can only be given after the potential risks and benefits of the relevant vaccine, risks of not having it and any alternative options have been explained to the individual.[10] 

Professor Olver, I question whether parents are being properly informed by healthcare providers before administration of the second dose of measles, mumps and rubella vaccine, (whether via the MMR or MMRV injection). 

In regards to point 2 above, I suggest parents are being pressured/coerced/manipulated to have the vaccine via the reward of Immunisation Related Payments.  While the Immunise Australia website notes that “benefits can be received without a child being fully immunised”[11] this is only the case after completion of an Immunisation exemption: Medical contraindication form[12] or Immunisation exemption: Conscientious objection form[13].  I suggest that neither of these forms in their current format is appropriate in the case of the questionable second dose of the live MMR vaccine.

In regards to point 4 above, I question whether parents are being properly informed of the potential risks and benefits of the second dose of the MMR vaccine.  There are no benefits to the child if the child is already immune after the first dose.  There are risks, i.e. possible side effects, as detailed in the PRIORIX and PRIORIX-TETRA Consumer Medicine Information leaflets and Product Information leaflets.  Are healthcare providers bringing this information to the attention of parents (and others)?

Reports of adverse events after MMR and MMRV vaccination have been submitted to the TGA’s Database of Adverse Events.[14] (Refer to reports attached.)  For example a TGA list of adverse events after vaccination with PRIORIX, generated for the dates 1 January 2012 to 20 November 2013, indicates 674 adverse event reports were made in that period.  253 of these cases occurred in four year olds.  Other age groups, (including adults), also reported adverse events after vaccination with PRIORIX.  As it is likely many of these children had already been vaccinated with PRIORIX at 12 months of age and were likely already immune, (if the PRIORIX MMR vaccine is as effective as claimed), they underwent revaccination for no benefit.

The MMRV vaccine was added to the Australian Government’s National Immunisation Program Schedule in July 2013[15], for vaccination of children at 18 months of age, after vaccination with the MMR at 12 months of age.  A TGA adverse event list generated for the dates 1 July 2013 to 20 November 2013 shows 80 reports of adverse events after vaccination with the PRIORIX-TETRA MMRV vaccine product.  If the children involved in these reports had already been vaccinated with the PRIORIX MMR vaccine at 12 months of age, again it is likely they were already immune to measles/mumps/rubella.

It should be recognised that adverse events after vaccination are likely to be under-reported.  The TGA acknowledges that reporting of adverse events to the TGA is voluntary, and that there is under-reporting in Australia, and around the world.[16]  In regards to the lack of safety information for the MMR vaccine, the Cochrane Collaboration’s systematic review of MMR vaccination notes: “The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate.”[17]

Again in relation to point 4 above, I also question whether “alternative options”, e.g. antibody titre testing to verify a response to MMR vaccination, are being explained to parents by healthcare providers.  It is possible that some careful parents might prefer to pay for antibody titre testing, rather than have their child revaccinated with a probably unnecessary second dose of live MMR vaccine.

Parents of small children might be surprised to discover that vaccination ‘best practice’ for companion animals is now more advanced than that for children, with international vaccination guidelines for dogs re live vaccines recommending antibody titre testing rather than an arbitrary ‘booster’, i.e.: “…the principles of ‘evidence-based veterinary medicine’ would dictate that testing for antibody status (for either pups or adult dogs) is a better practice than simply administering a vaccine booster on the basis that this should be ‘safe and cost less’”.[18]

Professor Olver, I question the ethics of coercing parents to have vaccinations of questionable benefit for their children.  According to the vaccine manufacturer’s data, it appears most seronegative individuals are likely to be immune after the first dose of MMR vaccine.  It appears likely from TGA adverse event database information that children (and possibly adults) have suffered after revaccination with a second dose of MMR vaccine.  I suggest there has been inadequate research undertaken on the possibly deleterious long-term effects of repeated vaccination, and so unnecessary vaccination should be avoided.

As the Australian Health Ethics Committee is responsible to advise the NHMRC on ethical issues relating to health, I would appreciate your urgent response on this matter to my email address elizmhart@gmail.com

Sincerely

Elizabeth Hart                         

*Please note this letter will be circulated to other parties.

cc:        Members of the NHMRC Australian Health Ethics Committee (AHEC)

  • Dr Gary Allen
  • Professor Vicki Anderson
  • Professor Samar Aoun
  • Professor Susan Dodds
  • Associate Professor Ian Kerridge
  • Dr Tammy Kimpton
  • Rabbi Aviva Kipen
  • Reverend Kevin McGovern
  • Professor John McGrath AM
  • Dr Eleanor Milligan
  • Professor Robin Mortimer
  • Ms Kay Oke
  • Professor Margaret Otlowski
  • Professor Debra Rickwood
  • Professor Wendy Rogers
  • Professor Loane Skene

and Professor Brian Martin, Social Sciences, University of Wollongong

References:  (All links accessible as at 19 March 2014.)


[1] National Immunisation Program Schedule from 1 July 2013: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips-ctn

[2] Immunise Australia Program.  Immunisation Related Payments for Parents. (Webpage dated 12 September 2013): http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/related-payments

[4] Ibid.

[5] Ibid.

[6] National Immunisation Program Schedule from 1 July 2013: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips-ctn

[8] GlaxoSmithKline PRIORIX Consumer Medicine Information Leaflet: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-05278-3

[9] GlaxoSmithKline PRIORIX-TETRA Consumer Medicine Information Leaflet: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-CMI-01069-1

[10] 2.1.3 Valid Consent. 2.1 Pre-vaccination. The Australian Immunisation Handbook. 10th Edition 2013: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/handbook10-2-1

[11] Immunise Australia Program.  Immunisation Related Payments for Parents. (Webpage dated 12 September 2013): http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/related-payments

[12] Immunisation exemption: Medical contraindication form: http://www.humanservices.gov.au/spw/customer/forms/resources/immu11.1310p.pdf on the Department of Human Services website: http://www.humanservices.gov.au/customer/forms/immu11

[13] Immunisation exemption: Conscientious objection form: http://www.humanservices.gov.au/spw/customer/forms/resources/immu12-1302en.pdf on the Department of Human Services website: http://www.humanservices.gov.au/customer/forms/immu12

[14] Adverse event information for medicines and medical devices can be accessed in the TGA’s Database of Adverse Notifications (DAEN): http://www.tga.gov.au/safety/daen.htm#.UyjVXfmSz-t

[15] National Immunisation Program Schedule from 1 July 2013: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips-ctn

[16] “Adverse event reports from consumers and health professionals to the TGA are voluntary, so there is under-reporting by these groups of adverse events related to therapeutic goods in Australia. This is the same around the world.”  About the DAEN – medicines: http://www.tga.gov.au/safety/daen-about.htm#.UyglSfmSz-t

[17] Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane

Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004407. DOI: 10.1002/14651858.CD004407.pub3.

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004407.pub3/abstract

[18] See page 7 under “Serological Testing to Determine the Duration of Immunity (DOI)”  in Day, M.J., Horzinek, M.C., Schultz, R.D. World Small Animal Veterinary Association’s (WSAVA) Guidelines for the Vaccination of Dogs and Cats. Journal of Small Animal Practice. Vol. 51. June 2010: http://www.wsava.org/sites/default/files/VaccinationGuidelines2010.pdf

 

 

Vaccination committees – power, influence, and ‘conflicts of interest’…

Vaccination committees provide advice to governments on vaccine products and ‘recommend’ the addition of new vaccine products to national vaccination schedules.

???????????????????????????????????????????????????????????????????????????These groups wield enormous power.   The members of these groups are part of a process that results in effectively mandating medical interventions (i.e. vaccinations) for healthy people.

The decisions these people make affect not only children and adults in their own countries, but can also impact internationally as the ripple effect of their decisions spreads around the world.

The powerful influence of these groups raises serious political and ethical questions about their impact on the bodily integrity of citizens, particularly ‘pre-citizens’, i.e. children.

As the decisions of these vaccination committees result in massive sales of vaccine products for pharmaceutical companies, it is vital that the process of adding vaccine products to national vaccination schedules is open and transparent, and that any potential ‘conflicts of interest’ of the members of these groups are accessible for public perusal.

For example, a register detailing the history of any relationships with the vaccine industry, e.g. research grants, consultancies, honorariums, plus any shareholdings in vaccine companies, royalties received, directorships etc, must be publicly accessible.  If a member indicates they have no potential conflicts of interest, this must be clearly recorded.

At this time, publicly accessible information on potential conflicts of interest for members of vaccination committees and groups is severely lacking.  

This is a matter I am continuing to investigate, see for example my post:  More re conflicts of interest and ‘the science of immunisation’.

Here are some committees/groups which are influential on vaccination policy: 

I am in the process of contacting these committees/groups to seek transparency and accountability for vaccination practice.

‘Informed consent’ and the Measles/Mumps/Rubella (MMR) vaccine – challenging the US Advisory Committee on Immunization Practices

As I have argued previously on Over-vaccination.net, it’s likely that most children will be immune after the first dose of the live Measles/Mumps/Rubella (MMR) vaccine.

However, mass populations of already immune children are being arbitrarily revaccinated with a second dose of the live MMR vaccine because a small proportion of children may not have responded to the first dose.  

In other words, millions of children are being over-vaccinated with the second dose of live MMR vaccine.

INFORMED CONSENTAre parents being given the opportunity to properly give their ‘informed consent’ to the second dose of live Measles/Mumps/Rubella (MMR) vaccine?  

See below my letter forwarded to Professor Jonathan Temte, Chair of the US Advisory Committee on Immunization Practices, challenging government mandated revaccination of children with the live MMR vaccine second dose.

_________________________________________

5 March 2014

Professor Temte

CHALLENGING MANDATED REVACCINATION OF CHILDREN WITH THE MEASLES/MUMPS/RUBELLA (MMR) VACCINE ‘BOOSTER’ SECOND DOSE

The Advisory Committee on Immunization Practices recommends that children in the United States receive two doses of live measles/mumps/rubella (MMR) vaccines at 12-15 months and 4-6 years.[1]  As a result of the ACIP’s recommendation, two MMR vaccine doses are mandated in many US states.[2]

However, according to the Merck M-M-R II Information Sheet, most seronegative children are likely to be immune after one dose of live MMR vaccine.[3]

In regards to measles vaccination, the Advisory Committee on Immunization Practices report on MMR vaccination (June 2013) admits that: “The second dose of measles-containing vaccine primarily was intended to induce immunity in the small percentage of persons who did not seroconvert after vaccination with the first dose of vaccine (primary vaccine failure).[4]

Given that most children are likely to be immunised after the first dose of live MMR vaccine, I question whether parents are being given the opportunity to properly give their ‘informed consent’ to the second dose of live MMR vaccine, also often described as a ‘booster’.[5]  This question is particularly pertinent as adverse events have been reported after MMR vaccination.

I request that the Advisory Committee on Immunization Practices respond to me on this matter, and I provide further supporting information below.

According to the Information Sheet for Merck’s M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) “clinical studies of 284 triple seronegative children, 11 months to 7 years of age, demonstrated that M-M-R II is highly immunogenic and generally well tolerated. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible persons.”[6]  (My emphasis.)

The Merck M-M-R II Information Sheet also notes: …a small percentage (1-5%) of vaccinees may fail to seroconvert after the primary dose”.[7]  It is my understanding that failure to seroconvert after vaccination with the primary dose is most likely due to interference of maternally derived antibodies, i.e. if the child is vaccinated at an age before maternally derived antibodies have waned.  Other reasons could be problems with the effectiveness of the vaccine product that results in vaccine failure, or that the individual is a poor responder.

No reference to published details of the “clinical studies of 284 triple seronegative children” is provided in Merck’s M-M-R II Information Sheet.  However, the ACIP report on MMR vaccination appears to support Merck’s information re the high seroconversion rate after primary vaccination, particularly in regards to the measles and rubella components of the MMR vaccine, (although there appears to be some ambiguity about the effectiveness of the mumps component of the MMR vaccine).[8]

Are healthcare providers informing parents (and other individuals) of the high likelihood of seroconversion after the first dose of live MMR vaccine, i.e. that most vaccinees are likely to be immune after the first dose of live MMR vaccine, given at the appropriate age? 

Are healthcare providers informing parents (and other individuals) of the option of antibody titre testing to verify a response to MMR vaccination?  It is possible that some careful parents (and other individuals) may prefer to pay for antibody titre testing before having the medical intervention of repeated MMR vaccination.  Parents of small children (and other individuals) might be surprised to discover that vaccination ‘best practice’ for companion animals is now more advanced than that for children, with international vaccination guidelines for dogs re live vaccines recommending antibody titre testing rather than an arbitrary ‘booster’, i.e. “…the principles of ‘evidence-based veterinary medicine’ would dictate that testing for antibody status (for either pups or adult dogs) is a better practice than simply administering a vaccine booster on the basis that this should be ‘safe and cost less’”.[9]

The blanket recommendation for two live MMR vaccine doses by the Advisory Committee on Immunization Practices appears to be at odds with the Authorizing Legislation of the US National Vaccine Injury Compensation Program, Sec. 300aa-26, i.e. legal representatives of any child or any individual receiving a vaccine set forth in the Vaccine Injury Table should be provided with information on the vaccine, including “a concise description of the benefits of the vaccine” and a concise description of the risks associated with the vaccine”.[10]

In regards to “a concise description of the benefits of the vaccine”, there are no benefits to the individual if the individual is already immune.  Most children are likely to be immune after the first live MMR vaccine dose, particularly the measles and rubella components.  This can be verified with an antibody titre test for those parents/individuals who want evidence of a response.

In regards to “a concise description of the risks associated with the vaccine”, there are risks, i.e. possible adverse reactions, as detailed in the Merck M-M-R II Information Sheet.[11]  Reports of adverse events after MMR vaccination have also been submitted to VAERS (the Vaccine Adverse Event Reporting System).[12]  Are healthcare providers bringing this information to the attention of parents (and other individuals)?

The VAERS database contains reports of children of four years and over who have experienced adverse events after vaccination with the MMR vaccine.  As it is likely many of these children had already been vaccinated with an MMR vaccine at 12-15 months of age, they were likely already immune (i.e. if the Merck M-M-R II vaccine is as effective as claimed), and they underwent revaccination for no benefit.  (It is also notable that reports of adults suffering adverse events after MMR vaccination are recorded in the VAERS database, which again raises the question whether these people were offered the option of antibody titre testing before MMR vaccination.)

VAERS is a passive surveillance system to which adverse events after vaccination are voluntarily reported.  The FDA has acknowledged that “VAERS is a crude tool” and that adverse events are likely to be under-reported.[13]  In regards to the lack of safety information re the MMR vaccine, the Cochrane Collaboration’s systematic review of MMR vaccination notes: “The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate.”[14]  I suggest there has been inadequate research undertaken on the possibly deleterious long-term effects of repeated vaccination, and that unnecessary vaccination should be avoided.

Professor Temte, I again question whether parents (and other individuals) are being properly informed by healthcare providers about MMR vaccination, in accordance with the Authorizing Legislation of the US National Vaccine Injury Compensation Program, Sec. 300aa-26, and whether ‘informed consent’ is being obtained before this medical intervention. 

As the US Advisory Committee on Immunization Practices is responsible for making recommendations on vaccine use, recommendations which have far-reaching impact not just in the United States, but are also influential around the world, I would appreciate your urgent response on this matter to my email address eliz.hart25@gmail.com

Sincerely

Elizabeth Hart                         

*Please note this letter will be circulated to other parties.

References:  (All links accessible as at 5 March 2014.)


[1] Recommended Immunization Schedules for Persons Aged 0 Through 18 Years, United States, 2014: http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

[2] Centers for Disease Control and Prevention. School and Childcare Vaccination Surveys. School Vaccination Requirements, Exemptions & Web links: http://www2a.cdc.gov/nip/schoolsurv/schimmrqmt.asp

[3] Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. M-M-R® II. (Measles, Mumps, and Rubella Virus Vaccine Live). Information Sheet. 9912202: http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf

[4] Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Vol. 62, No.4. June 14, 2013: http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf  (See page 3.)

[5] For example, the CDC “Measles Vaccination: Who Needs It?” webpage states: “A second dose of the vaccine is recommended to protect those 5% who did not develop immunity in the first dose and to give “booster” effect to those who did develop an immune response.”  http://www.cdc.gov/vaccines/vpd-vac/measles/vacc-in-short.htm  I question the benefit of this so-called ‘booster’ effect for children who are already immune, particularly to measles and rubella.

[7] Ibid.

[8] Op cit. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps:  http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf   (See pages 7-11.)

[9] Day, M.J., Horzinek, M.C., Schultz, R.D. World Small Animal Veterinary Association’s (WSAVA) Guidelines for the Vaccination of Dogs and Cats. Journal of Small Animal Practice. Vol. 51. June 2010: http://www.wsava.org/sites/default/files/VaccinationGuidelines2010.pdf    (See page 7.)

[10] 300aa-26. Vaccine information. National Vaccine Injury Compensation Program: http://www.hrsa.gov/vaccinecompensation/authoringleg.pdf

[12] Vaccine Adverse Event Reporting System (VAERS): http://vaers.hhs.gov/data/index

[14] Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004407. DOI: 10.1002/14651858.CD004407.pub3.  http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004407.pub3/abstract